世界卫生组织细菌病原体优先清单2017与2024:抗微生物耐药挑战与机遇
本文分析WHO通过细菌病原体优先清单(BPPL)、全球行动计划及监测与抗菌药物管理项目应对抗微生物耐药(AMR)的努力,审视BPPL 2017的进展与BPPL 2024面临的挑战,并探讨研发与政策监管两类路径及生物膜破坏、纳米技术等新兴策略。
要点
- WHO通过BPPL、全球行动计划和监测与管理项目应对AMR。
- 文章分析BPPL 2017的进展及BPPL 2024面临的挑战。
- 探讨研发与政策监管两类路径及多种新兴抗AMR策略。
核心结论
- AMR使感染更难或无法治疗,增加发病和死亡,WHO通过BPPL等努力应对,需协调行动与持续承诺。
研究设计与样本
- 本文为综述,分析WHO抗击AMR的努力,包括BPPL、全球行动计划及监测与管理项目,并审视BPPL 2017进展与BPPL 2024挑战。
主要发现
- 文章探讨研发与政策监管两类抗AMR路径,并强调生物膜破坏、纳米技术、抗生素耐药破坏剂、抗体-抗生素偶联物、快速检测工具及噬菌体疗法等新兴策略。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibiotic resistance, in a broader perspective, antimicrobial resistance (AMR) presents a formidable global health challenge, threatening the effectiveness of antibiotics and other antimicrobial agents. As a result, AMR has become more challenging or even impossible to treat, leading to increased morbidity and mortality. The World Health Organisation (WHO) has been at the forefront of international efforts to combat AMR by sensitizing the world about the pressing need to tackle AMR to save the future of the human race. This article analyses WHO's efforts to combat AMR, including creating the Bacterial Pathogen Priority List (BPPL), developing a global action plan to address AMR and promoting surveillance and stewardship programmes. This article also examines the progress achieved by BPPL 2017 and the challenges ahead for BPPL 2024. Additionally, this article explores various efforts to combat AMR through two major approaches, like 'research and development' and 'the policy and regulation-based' approach. This article underscores various emerging strategies to tackle AMR, for example, biofilm disruption, nanotechnology, antibiotic resistance breakers, antibody-antibiotic conjugates, rapid detection tools and alternative therapies like phage therapy, antimicrobial peptides, CRISPR-Cas system, probiotics and microbiota modulations. This article also highlights the importance of coordinated actions and sustained commitment to safeguarding public health and ensuring the continued effectiveness of antimicrobial therapies.
引用
- Krishnaprasad VH, Nayak V, Kumar S, et al. World Health Organisation's Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: 'challenges and opportunities'. J Antimicrob Chemother. 2025. PMID: 40424180. doi:10.1093/jac/dkaf167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。